No Data
No Data
AnaptysBio Analyst Ratings
Cautious Hold Rating on AnaptysBio Amid Mixed Clinical Trial Results and Strategic Uncertainties
Express News | AnaptysBio Inc : Guggenheim Raises Target Price to $52 From $36
A Quick Look at Today's Ratings for AnaptysBio(ANAB.US), With a Forecast Between $22 to $57
AnaptysBio Insiders Sell US$3.6m Of Stock, Possibly Signalling Caution
H.C. Wainwright Maintains AnaptysBio(ANAB.US) With Hold Rating, Maintains Target Price $22
damoose :
Yanfang Kuang : Thank you
74693490 : How much time do you spend on Stocks every day? I remember one time you posted on your Watchlist in the middle of the night, and then at five in the morning the next day you were commenting again. Overextending yourself like this will cause your body to collapse.
Day Lily : Thank you
)
(silent stalker #45,328
Veteran Analyst : Do you use a stock scanner to do the screening? Which software is good? Thanks.
View more comments...